Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
skip to main content
10.1145/3449258.3449262acmotherconferencesArticle/Chapter ViewAbstractPublication PagesiccbbConference Proceedingsconference-collections
research-article

A Framework for Route Based Pathway Analysis of Gene Expression Data

Published: 22 June 2021 Publication History

Abstract

Pathway analysis is a key step in genomics study to reduce the data complexity and associate prior biological knowledge. Over representation analysis (ORA), Functional class scoring (FCS), and Topology based (TB) analysis are considered as three generations of pathway analysis techniques. These methods only detect the differential activity of an entire pathway, thereby ignoring the importance of routes and sections within the pathway. A novel route-based pathway analysis framework, Route based Pathway Analysis in Cohorts (rPAC), is discussed in this paper which uses pathway topology in true sense by identifying and scoring individual routes within pathways. Activity scores and p-values are calculated for all signaling and effector routes from KEGG signaling pathways with transcriptomics data from each sample in the given cohort. Overall route activity in a cohort is assessed in terms of two summary metrics, “Proportion of Significance” (PS) and “Average Route Score” (ARS). A systematic evaluation based on large number of simulated data showed rPAC significantly outperforming the traditional pathway analysis methods. Case studies of three epithelial cancers from The Cancer Genome Atlas (TCGA) repository revealed that some pathway routes (e.g., tight junction, Th17 cell differentiation, adipocytokine signaling etc.) can notably differentiate cancer types, while other pathway routes that are related to lipid metabolism and adipocytes metabolism are co-regulated in different cancers. While most of the findings are corroborated by the current understanding of cancer biology, many previously uncharacterized mechanisms were identified by rPAC analysis, exhibiting the potential to yield new insights into cancer phenotypes.

References

[1]
A. Subramanian, P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A. Paulovich, S.L. Pomeroy, T.R. Golub, E.S. Lander and J.P. Mesirov, "Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles," Proceedings of the National Academy of Sciences, vol. 102, pp. 15545-15550, 2005.
[2]
H. Ogata, S. Goto, K. Sato, W. Fujibuchi, H. Bono and M. Kanehisa, "KEGG: Kyoto Encyclopedia of Genes and Genomes," Nucleic Acids Research, vol. 27, pp. 29-34, Jan 1, 1999.
[3]
B. Jassal, "The reactome pathway knowledgebase," Nucleic Acids Research, vol. 48, pp. D498-D503, Jan 8, 2020.
[4]
A.L. Tarca, S. Draghici, P. Khatri, S.S. Hassan, P. Mittal, J. Kim, C.J. Kim, J.P. Kusanovic and R. Romero, "A novel signaling pathway impact analysis," Bioinformatics, vol. 25, pp. 75-82, Jan 1, 2009.
[5]
C.J. Vaske, S.C. Benz, J.Z. Sanborn, D. Earl, C. Szeto, J. Zhu, D. Haussler and J.M. Stuart, "Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM," Bioinformatics (Oxford, England), vol. 26, pp. i237-i245, Jun 15, 2010.
[6]
C. Liu, R. Lehtonen and S. Hautaniemi, "PerPAS," Tcbb, vol. 15, pp. 1022-1027, May 1, 2018.
[7]
T.M. Therneau and P.M. Grambsch, Modeling Survival Data: Extending the Cox Model, Springer-Verlag New York, 2020.
[8]
B.J. Coventry, P. Lee, D. Gibbs and D.N.J. Hart, "Dendritic cell density and activation status in human breast cancer – CD1a, CMRF-44, CMRF-56 and CD-83 expression," British Journal of Cancer, vol. 86, pp. 546-551, 2002.
[9]
C. Lee, L. Chen, C. Yu, W. Lin, V.C. Lin, C. Huang, T. Lu, S. Huang and B. Bao, "Prognostic Value of CD1B in Localised Prostate Cancer," International Journal of Environmental Research and Public Health, vol. 16, pp. 4723, 2019.
[10]
S. Qie and J.A. Diehl, "Cyclin D1, cancer progression, and opportunities in cancer treatment," J Mol Med, vol. 94, pp. 1313-1326, 2016.
[11]
N. Zaidi, L. Lupien, N.B. Kuemmerle, W.B. Kinlaw, J.V. Swinnen and K. Smans, "Lipogenesis and lipolysis: The pathways exploited by the cancer cells to acquire fatty acids," Progress in Lipid Research, vol. 52, pp. 585-589, 2013.
[12]
J.S. Hansen, S. de Maré, H.A. Jones, O. Göransson and K. Lindkvist-Petersson, "Visualization of lipid directed dynamics of perilipin 1 in human primary adipocytes," Scientific Reports, vol. 7, pp. 15011-14, 2017.
[13]
X. Zhao, J. Liu, S. Ge, C. Chen, S. Li, X. Wu, X. Feng, Y. Wang and D. Cai, "Saikosaponin A Inhibits Breast Cancer by Regulating Th1/Th2 Balance," Frontiers in Pharmacology, vol. 10, pp. 624, 2019.
[14]
X. Dai, T. Li, Z. Bai, Y. Yang, X. Liu, J. Zhan and B. Shi, "Breast cancer intrinsic subtype classification, clinical use and future trends," American Journal of Cancer Research, vol. 5, pp. 2929-2943, 2015.
[15]
E. Tomaskovic-Crook, E.W. Thompson and J.P. Thiery, "Epithelial to mesenchymal transition and breast cancer," Breast Cancer Research: BCR, vol. 11, pp. 213, 2009.
[16]
M.F. Mercogliano, S. Bruni, P.V. Elizalde and R. Schillaci, "Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer," Frontiers in Oncology, vol. 10, pp. 584, 2020.
[17]
D. Colussi, G. Brandi, F. Bazzoli and L. Ricciardiello, "Molecular Pathways Involved in Colorectal Cancer: Implications for Disease Behavior and Prevention," International Journal of Molecular Sciences, vol. 14, pp. 16365-16385, Aug 7, 2013.
[18]
M.N. Vansaun, "Molecular Pathways: Adiponectin and Leptin Signaling in Cancer," Clinical Cancer Research, vol. 19, pp. 1926-1932, Apr 15, 2013.

Cited By

View all
  • (2022)Computational Pathways Analysis and Personalized Medicine in HER2-Positive Breast CancerCurrent Pharmacogenomics and Personalized Medicine10.2174/187569211966622040711404419:1(40-52)Online publication date: Apr-2022
Index terms have been assigned to the content through auto-classification.

Recommendations

Comments

Information & Contributors

Information

Published In

cover image ACM Other conferences
ICCBB '20: Proceedings of the 2020 4th International Conference on Computational Biology and Bioinformatics
December 2020
80 pages
ISBN:9781450388443
DOI:10.1145/3449258
Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than the author(s) must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from [email protected].

Publisher

Association for Computing Machinery

New York, NY, United States

Publication History

Published: 22 June 2021

Permissions

Request permissions for this article.

Check for updates

Author Tags

  1. TCGA data analysis
  2. topology and route-based pathway analysis

Qualifiers

  • Research-article
  • Research
  • Refereed limited

Conference

ICCBB '20

Contributors

Other Metrics

Bibliometrics & Citations

Bibliometrics

Article Metrics

  • Downloads (Last 12 months)3
  • Downloads (Last 6 weeks)0
Reflects downloads up to 05 Mar 2025

Other Metrics

Citations

Cited By

View all
  • (2022)Computational Pathways Analysis and Personalized Medicine in HER2-Positive Breast CancerCurrent Pharmacogenomics and Personalized Medicine10.2174/187569211966622040711404419:1(40-52)Online publication date: Apr-2022

View Options

Login options

View options

PDF

View or Download as a PDF file.

PDF

eReader

View online with eReader.

eReader

HTML Format

View this article in HTML Format.

HTML Format

Figures

Tables

Media

Share

Share

Share this Publication link

Share on social media